TrialInternational journal of clinical oncology2018

Efficacy and safety of third-line molecular-targeted therapy in metastatic renal cell carcinoma resistant to first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor and second-line therapy.

Hiroki Ishihara et al.PubMed ↗Publisher ↗

No numbers read from the abstract.